Pharma Focus Asia
MasterControl - Avoid Falling Behind the Pharma Market

Novel Therapy, Sotorasib, Discovered for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Amgen novel therapy Sotorasib discovered for the treatment of patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients with KRAS G12C Mutation.

Sotorasib, an investigational small molecule that selectively and irreversibly targets KRASG12C, is developed for the treatment of advanced or metastatic NSCLC in patient population.

KRAS G12C is the most common KRAS mutation in NSCLC. It acts as a biomarker of poor prognosis in patients diagnosed with NSCLC, which generally improves G12C-specific inhibitors.

NSCLC, the lung cancer, results in approximately 80-85 per cent of cases worldwide. Studies have shown that about 3-5 per cent of KRAS G12C mutation is usually found in smokers.

Novel investigational drug sotorasib is designed to treat patients with advanced solid tumor with the KRAS G12C mutation and to deal with longstanding unmet medical need for these cancers.

Sotorasib received Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the treatment of Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC).

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Increasing the likelihood of your drug approvalMasterControl - Manufacturing demoMasterControl - QMS demoBora Pharmaceuticals - Free WhitepaperThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayThermo Fisher Scientific - PeptonesMerck - Mobius® productsMedical Fair Thailand 20235th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 2023Reuters Events - Pharma Customer Engagement USA 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023
MasterControl - 6 Essential Features in an eQMS